These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The treatment of essential hyperlipidemia with clofibrate]. Reuter W, Seifert A. Z Gesamte Inn Med; 1969 Jan 01; 24(1):Suppl:184-7. PubMed ID: 4918619 [No Abstract] [Full Text] [Related]
5. [Treatment of essential hyperlipemia with clofibrate]. Reuter W, Seifert A. Z Gesamte Inn Med; 1969 Jun 15; 24(12):184-7. PubMed ID: 5404292 [No Abstract] [Full Text] [Related]
7. Type IIa hyperlipoproteinaemia. An evaluation of four therapeutic regimens. Watermeyer GS, Mann JI, Truswell AS, Levy I. S Afr Med J; 1975 Apr 05; 49(15):631-4. PubMed ID: 1094562 [Abstract] [Full Text] [Related]
9. [Clinical trial of C.P.I.B. (clofibrate) in treatment of diabetic hypertriglyceridemia]. Warembourg H, Jaillard J. Lille Med; 1968 Jan 05; 13(1):Suppl:5-8. PubMed ID: 5745605 [No Abstract] [Full Text] [Related]
10. [Clinical experimental lipid metabolism studies with essential phospholipids taking into account the arteriosclerosis problem]. Hammerl H, Pichler O, Studlar M. Wien Med Wochenschr; 1966 Apr 16; 116(16):348-52. PubMed ID: 5985190 [No Abstract] [Full Text] [Related]
17. Effect of a hypolipidaemic drug (CH 13,437) on plasma and tissue lipids, and on the intravenous fat tolerance in man. Boberg J, Carlson LA, Fröberg SO, Orö L. Atherosclerosis; 1970 Apr 16; 11(2):353-60. PubMed ID: 4353910 [No Abstract] [Full Text] [Related]
18. [Clinical-experimental studies on lipid metabolism using Regelan]. Hammerl H. Wien Klin Wochenschr; 1967 Sep 29; 79(39):720-2. PubMed ID: 4875575 [No Abstract] [Full Text] [Related]